140 related articles for article (PubMed ID: 14871970)
1. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma.
Tamborini E; Bonadiman L; Greco A; Gronchi A; Riva C; Bertulli R; Casali PG; Pierotti MA; Pilotti S
Clin Cancer Res; 2004 Feb; 10(3):938-43. PubMed ID: 14871970
[TBL] [Abstract][Full Text] [Related]
2. c-KIT and c-KIT ligand (SCF) in synovial sarcoma (SS): an mRNA expression analysis in 23 cases.
Tamborini E; Papini D; Mezzelani A; Riva C; Azzarelli A; Sozzi G; Pierotti MA; Pilotti S
Br J Cancer; 2001 Aug; 85(3):405-11. PubMed ID: 11487273
[TBL] [Abstract][Full Text] [Related]
3. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.
Lagonigro MS; Tamborini E; Negri T; Staurengo S; Dagrada GP; Miselli F; Gabanti E; Greco A; Casali PG; Carbone A; Pierotti MA; Pilotti S
J Pathol; 2006 Apr; 208(5):615-23. PubMed ID: 16470538
[TBL] [Abstract][Full Text] [Related]
4. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors.
Bozzi F; Tamborini E; Negri T; Pastore E; Ferrari A; Luksch R; Casanova M; Pierotti MA; Bellani FF; Pilotti S
Cancer; 2007 Apr; 109(8):1638-45. PubMed ID: 17342771
[TBL] [Abstract][Full Text] [Related]
5. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
[TBL] [Abstract][Full Text] [Related]
6. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809
[TBL] [Abstract][Full Text] [Related]
7. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
Thomas DG; Giordano TJ; Sanders D; Biermann S; Sondak VK; Trent JC; Yu D; Pollock RE; Baker L
Cancer; 2005 Feb; 103(4):830-8. PubMed ID: 15641030
[TBL] [Abstract][Full Text] [Related]
8. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
[TBL] [Abstract][Full Text] [Related]
9. Stat1 associates with c-kit and is activated in response to stem cell factor.
Deberry C; Mou S; Linnekin D
Biochem J; 1997 Oct; 327 ( Pt 1)(Pt 1):73-80. PubMed ID: 9355737
[TBL] [Abstract][Full Text] [Related]
10. Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism.
Théou-Anton N; Tabone S; Brouty-Boyé D; Saffroy R; Ronnstrand L; Lemoine A; Emile JF
Br J Cancer; 2006 Apr; 94(8):1180-5. PubMed ID: 16570044
[TBL] [Abstract][Full Text] [Related]
11. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
[TBL] [Abstract][Full Text] [Related]
12. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.
Tamborini E; Casieri P; Miselli F; Orsenigo M; Negri T; Piacenza C; Stacchiotti S; Gronchi A; Pastorino U; Pierotti MA; Pilotti S
J Pathol; 2007 Jun; 212(2):227-35. PubMed ID: 17471466
[TBL] [Abstract][Full Text] [Related]
13. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas.
Reis RM; Martins A; Ribeiro SA; Basto D; Longatto-Filho A; Schmitt FC; Lopes JM
Cell Oncol; 2005; 27(5-6):319-26. PubMed ID: 16373964
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression.
Kadivar A; Ibrahim Noordin M; Aditya A; Kamalidehghan B; Davoudi ET; Sedghi R; Akbari Javar H
Int J Mol Med; 2018 Jul; 42(1):414-424. PubMed ID: 29620139
[TBL] [Abstract][Full Text] [Related]
16. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer.
Tamborini E; Bonadiman L; Negri T; Greco A; Staurengo S; Bidoli P; Pastorino U; Pierotti MA; Pilotti S
Clin Cancer Res; 2004 Dec; 10(24):8214-9. PubMed ID: 15623596
[TBL] [Abstract][Full Text] [Related]
17. Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer.
Paronetto MP; Farini D; Sammarco I; Maturo G; Vespasiani G; Geremia R; Rossi P; Sette C
Am J Pathol; 2004 Apr; 164(4):1243-51. PubMed ID: 15039213
[TBL] [Abstract][Full Text] [Related]
18. Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
Bondzi C; Litz J; Dent P; Krystal GW
Cell Growth Differ; 2000 Jun; 11(6):305-14. PubMed ID: 10910097
[TBL] [Abstract][Full Text] [Related]
19. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
Fjällskog ML; Lejonklou MH; Oberg KE; Eriksson BK; Janson ET
Clin Cancer Res; 2003 Apr; 9(4):1469-73. PubMed ID: 12684421
[TBL] [Abstract][Full Text] [Related]
20. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
